Patient characteristics according to CALCRL expression
| Variables . | CALCRL expression . | . | |
|---|---|---|---|
| Low . | High . | P value . | |
| N | 203 | 81 | |
| Age, y | .38* | ||
| Median (range) | 10 (0-23) | 10 (0-20) | |
| Sex, no. (%) | .15† | ||
| Male | 102 (50.2) | 49 (60.5) | |
| Female | 101 (49.8) | 32 (39.5) | |
| FAB, no. (%) | .059† | ||
| M0 | 6 (3.0) | 1 (1.2) | |
| M1 | 28 (13.8) | 8 (9.9) | |
| M2 | 47 (23.2) | 23 (28.4) | |
| M4 | 41 (20.2) | 24 (29.6) | |
| M5 | 47 (23.2) | 7 (8.6) | |
| M6 | 3 (1.5) | 1 (1.2) | |
| M7 | 8 (3.9) | 1 (1.2) | |
| NOS | 10 (4.9) | 7 (8.6) | |
| Missing | 13 (6.4) | 9 (11.1) | |
| WBC, ×109/L | .27* | ||
| Median (range) | 40.5 (0.9-519.0) | 51.1 (2.0-446.0) | |
| PB blasts, % | .67* | ||
| Median (range) | 61 (0-97) | 61 (0-97) | |
| BM blasts, % | .023* | ||
| Median (range) | 77 (20-99) | 70 (14-100) | |
| CNS involvement, no. (%) | .81* | ||
| Present | 16 (7.9) | 5 (6.2) | |
| Absent | 187 (92.1) | 76 (93.8) | |
| Extramedullary AML, no. (%) | .64* | ||
| Present | 23 (11.3) | 7 (8.6) | |
| Absent | 179 (88.2) | 74 (91.4) | |
| Missing | 1 (0.5) | 0 (0.0) | |
| Trial, no. (%) | .68† | ||
| AAML03P1 | 44 (21.7) | 16 (19.8) | |
| AAML0531 | 132 (65.0) | 51 (63.0) | |
| CCG-2961 | 27 (13.3) | 14 (17.3) | |
| HSCT in 1 CR, no. (%) | .21† | ||
| Yes | 22 (10.8) | 13 (16.0) | |
| No | 159 (10.8) | 54 (66.7) | |
| Missing | 22 (10.8) | 14 (17.3) | |
| Cytogenetics, no. (%)‡ | |||
| t(8;21) | 44 (22.8) | 1 (1.4) | <.0001§ |
| inv(16)/t(16;16) | 21 (10.9) | 21 (28.4) | .0009† |
| Normal | 47 (24.4) | 23 (31.1) | .34† |
| t(9;11) | 15 (7.8) | 1 (1.4) | .080§ |
| t(6;9) | 1 (0.5) | 2 (2.7) | .19§ |
| t(9;22) | — | — | |
| t(v;11q23) | 20 (10.4) | 3 (4.1) | .14§ |
| inv(3)/t(3;3) | 0 (0.0) | 1 (1.4) | .27§ |
| del(5q)/-5 | 1 (0.5) | 0 (0.0) | 1.00§ |
| −7 | 1 (0.5) | 1 (1.4) | .48§ |
| −17/abn(17p) | 2 (1.1) | 3 (5.3) | .092§ |
| Complex | 15 (7.8) | 4 (5.4) | .60§ |
| Monosomal | 3 (1.6) | 3 (4.1) | .35§ |
| Other | 30 (15.5) | 16 (21.6) | .32† |
| Missing | 10 (4.9) | 7 (8.6) | |
| FLT3-ITD, no. (%) | .0001† | ||
| Present | 22 (10.8) | 25 (30.9) | .43† |
| High allelic ratio | 14 (63.6) | 12 (48.0) | |
| Low allelic ratio | 8 (36.4) | 13 (52.0) | |
| Absent | 181 (89.2) | 56 (69.1) | |
| NPM1, no. (%) | .54§ | ||
| Mutated | 12 (5.9) | 7 (8.6) | |
| Wild type | 185 (91.1) | 70 (86.4) | |
| Missing | 6 (3.0) | 4 (4.9) | |
| CEBPA, no. (%) | .0076§ | ||
| Mutated | 16 (7.9) | 0 (0.0) | |
| Wild type | 185 (91.1) | 79 (97.5) | |
| Missing | 2 (1.0) | 2 (2.5) | |
| Risk group, no. (%)ǁ | .068† | ||
| Favorable | 89 (43.8) | 27 (33.3) | |
| Intermediate | 86 (42.4) | 34 (42.0) | |
| Adverse | 16 (7.9) | 13 (16.0) | |
| Missing | 12 (5.9) | 7 (8.6) | |
| Variables . | CALCRL expression . | . | |
|---|---|---|---|
| Low . | High . | P value . | |
| N | 203 | 81 | |
| Age, y | .38* | ||
| Median (range) | 10 (0-23) | 10 (0-20) | |
| Sex, no. (%) | .15† | ||
| Male | 102 (50.2) | 49 (60.5) | |
| Female | 101 (49.8) | 32 (39.5) | |
| FAB, no. (%) | .059† | ||
| M0 | 6 (3.0) | 1 (1.2) | |
| M1 | 28 (13.8) | 8 (9.9) | |
| M2 | 47 (23.2) | 23 (28.4) | |
| M4 | 41 (20.2) | 24 (29.6) | |
| M5 | 47 (23.2) | 7 (8.6) | |
| M6 | 3 (1.5) | 1 (1.2) | |
| M7 | 8 (3.9) | 1 (1.2) | |
| NOS | 10 (4.9) | 7 (8.6) | |
| Missing | 13 (6.4) | 9 (11.1) | |
| WBC, ×109/L | .27* | ||
| Median (range) | 40.5 (0.9-519.0) | 51.1 (2.0-446.0) | |
| PB blasts, % | .67* | ||
| Median (range) | 61 (0-97) | 61 (0-97) | |
| BM blasts, % | .023* | ||
| Median (range) | 77 (20-99) | 70 (14-100) | |
| CNS involvement, no. (%) | .81* | ||
| Present | 16 (7.9) | 5 (6.2) | |
| Absent | 187 (92.1) | 76 (93.8) | |
| Extramedullary AML, no. (%) | .64* | ||
| Present | 23 (11.3) | 7 (8.6) | |
| Absent | 179 (88.2) | 74 (91.4) | |
| Missing | 1 (0.5) | 0 (0.0) | |
| Trial, no. (%) | .68† | ||
| AAML03P1 | 44 (21.7) | 16 (19.8) | |
| AAML0531 | 132 (65.0) | 51 (63.0) | |
| CCG-2961 | 27 (13.3) | 14 (17.3) | |
| HSCT in 1 CR, no. (%) | .21† | ||
| Yes | 22 (10.8) | 13 (16.0) | |
| No | 159 (10.8) | 54 (66.7) | |
| Missing | 22 (10.8) | 14 (17.3) | |
| Cytogenetics, no. (%)‡ | |||
| t(8;21) | 44 (22.8) | 1 (1.4) | <.0001§ |
| inv(16)/t(16;16) | 21 (10.9) | 21 (28.4) | .0009† |
| Normal | 47 (24.4) | 23 (31.1) | .34† |
| t(9;11) | 15 (7.8) | 1 (1.4) | .080§ |
| t(6;9) | 1 (0.5) | 2 (2.7) | .19§ |
| t(9;22) | — | — | |
| t(v;11q23) | 20 (10.4) | 3 (4.1) | .14§ |
| inv(3)/t(3;3) | 0 (0.0) | 1 (1.4) | .27§ |
| del(5q)/-5 | 1 (0.5) | 0 (0.0) | 1.00§ |
| −7 | 1 (0.5) | 1 (1.4) | .48§ |
| −17/abn(17p) | 2 (1.1) | 3 (5.3) | .092§ |
| Complex | 15 (7.8) | 4 (5.4) | .60§ |
| Monosomal | 3 (1.6) | 3 (4.1) | .35§ |
| Other | 30 (15.5) | 16 (21.6) | .32† |
| Missing | 10 (4.9) | 7 (8.6) | |
| FLT3-ITD, no. (%) | .0001† | ||
| Present | 22 (10.8) | 25 (30.9) | .43† |
| High allelic ratio | 14 (63.6) | 12 (48.0) | |
| Low allelic ratio | 8 (36.4) | 13 (52.0) | |
| Absent | 181 (89.2) | 56 (69.1) | |
| NPM1, no. (%) | .54§ | ||
| Mutated | 12 (5.9) | 7 (8.6) | |
| Wild type | 185 (91.1) | 70 (86.4) | |
| Missing | 6 (3.0) | 4 (4.9) | |
| CEBPA, no. (%) | .0076§ | ||
| Mutated | 16 (7.9) | 0 (0.0) | |
| Wild type | 185 (91.1) | 79 (97.5) | |
| Missing | 2 (1.0) | 2 (2.5) | |
| Risk group, no. (%)ǁ | .068† | ||
| Favorable | 89 (43.8) | 27 (33.3) | |
| Intermediate | 86 (42.4) | 34 (42.0) | |
| Adverse | 16 (7.9) | 13 (16.0) | |
| Missing | 12 (5.9) | 7 (8.6) | |
Significant P values are marked in bold.
BM, bone marrow; CEPBA, CCAAT/enhancer binding protein α; CNS, central nervous system; FAB, French-American-British classification; FLT3-ITD, internal tandem duplication of the FLT3 gene; HSCT, allogeneic hematopoietic stem cell transplantation; NPM1, nucleophosmin-1; PB, peripheral blood.
Mann-Whitney test.
χ2 test.
Patients may be counted more than once in cases with 2 or more coexisting cytogenetic abnormalities.
Fisher’s exact test.
Risk groups were defined as described19 as favorable [t(8;21), inv(16)/t(16;16), NPM1 or CEBPA mutations in the absence of FLT3-ITD], adverse [-5/del(5q), -7, or high FLT3-ITD allelic ratio], and intermediate (all other patients with available genetic data).